Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C.

Published on Aug 1, 2021in BMJ Open Gastroenterology
· DOI :10.1136/BMJGAST-2021-000721
Sources
Abstract
Hepatitis C virus (HCV) infection is a major public health concern worldwide, raising important medical and economic issues. HCV-related end-stage liver disease is one of the most common indications for hepatic transplantation. Chronic hepatitis C is also assimilated to a systemic disease because of multiple extrahepatic manifestations, including lymphoproliferative disorders. The revolution of HCV treatment with the advent of direct-acting antivirals has significantly improved the management with high antiviral efficacy and good safety profile compared with old regimens, thus allowing good outcomes on hepatic and extrahepatic symptoms. However, with the widespread use of these new agents, controversial concerns about unexpected increasing cases of hepatocellular carcinoma were reported. We now report the case of a patient presenting with HCV-related cirrhosis, treated with direct-antiviral therapy and diagnosed with primary hepatic lymphoma shortly after the end of the treatment.
References7
Newest
#1Tomonari ShimagakiH-Index: 4
#2Takashi MaedaH-Index: 28
Last. Hiroyuki MatsudaH-Index: 61
view all 14 authors...
A 72-year-old man who was treated with a combination of simeprevir with peginterferon and ribavirin for hepatitis C virus (HCV) infection (genotype 1b) 5 years ago and has been treated as sustained virological response, was found to have a 2.6 cm tumourous lesion in the medial segment of the liver. He underwent a left hepatic lobectomy with a diagnosis of suspected hepatocellular carcinoma. The patient remained stable in follow-up CT every 3 months for more than 14 months. 1. Hepatocellular carc...
Source
#1Hashem B. El-Serag (BCM: Baylor College of Medicine)H-Index: 121
#2Israel Christie (BCM: Baylor College of Medicine)H-Index: 2
Last. Jennifer R. Kramer (BCM: Baylor College of Medicine)H-Index: 53
view all 6 authors...
BACKGROUND: Direct-acting anti-viral (DAA) therapy may have a beneficial role in extrahepatic manifestations of hepatitis C virus (HCV) infection. However, the available data are limited. AIM: To examine the effects of DAA treatment on the risk of several extrahepatic manifestations of HCV. METHODS: We conducted a retrospective cohort study of patients from the US Department of Veterans Affairs Corporate Data Warehouse who had a positive HCV RNA test and received first course of DAAs between 201...
Source
#1Xavier A AndradeH-Index: 3
#2Luis H PazH-Index: 4
Last. Anshu SinghH-Index: 2
view all 8 authors...
Introduction: Hepatitis C infection is highly prevalent worldwide and has a well-known association with B-cell lymphoid malignancies. Antiviral therapy has successfully decreased the rate of liver cirrhosis and improved the outcome in patients with hepatitis C-associated lymphomas. However, although there are a few case reports of aggressive lymphomas after successful hepatitis C therapy, the mechanism behind this association remains unclear. Case Presentation: We present the case of a 55-year-o...
Source
#1Alvise SchiavinatoH-Index: 8
#2Alberto Zanetto (UNIPD: University of Padua)H-Index: 15
Last. Mario PlebaniH-Index: 105
view all 14 authors...
Hepatitis C Virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality. In this study we used flow cytometry to evaluate the effect of Interferon-free antiviral treatment on peripheral blood lymphocytes in HCV patients with or without associated lymphoproliferative disorders. Flow cytometry analysis of peripheral blood lymphocytes were ...
Source
#1Rosanna Villani (University of Foggia)H-Index: 13
#2Antonio Facciorusso (University of Foggia)H-Index: 20
Last. Gaetano Serviddio (University of Foggia)H-Index: 45
view all 8 authors...
Background Novel direct-acting antivirals (DAAs) have completely changed the panorama of hepatitis C due to their high efficacy and optimal safety profile. Unfortunately, an unexpectedly high rate of early recurrence of hepatocellular carcinoma has been reported within weeks of starting treatment, but the mechanism is not known. Methods We monitored the serum level of vascular endothelial growth factor (VEGF) and changes in the pattern of circulating interleukins in 103 chronic hepatitis C patie...
Source
#1Huixiang YangH-Index: 1
#2Zhiyong WangH-Index: 1
Last. Zemin WangH-Index: 1
view all 4 authors...
Aim. To investigate the correlation and significance between the urine soluble Fas (sFas) and vascular endothelial growth factor (VEGF) expression in patients with urothelial bladder carcinoma (UC). Methods. The level of sFas was measured by enzyme-linked immunosorbent assay (ELISA) and the expression of VEGF protein in UC surgical specimens was screened by immunohistochemical method. These data were analyzed through SPSS 13.0 software. Results. The urinary sFas levels were significantly higher ...
Source
#1Jing Yang (ZJU: Zhejiang University)H-Index: 1
#2Wenlu Li (ZJU: Zhejiang University)H-Index: 1
Last. Ying Chai (ZJU: Zhejiang University)H-Index: 1
view all 6 authors...
Vascular endothelial growth factor (VEGF) plays a vital role in the progression of Non-Hodgkin's lymphoma (NHL). Although multiple studies have investigated the relationship between VEGF expression and prognosis of NHL, these studies have yielded conflicting results. Therefore, we performed a meta-analysis to evaluate the role of VEGF in the prognosis of NHL patients. We systematically searched eligible studies from databases and determined that there was a significant correlation between VEGF o...
Source
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.